Cargando…
Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
PURPOSE: To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well as on central macular thickness (CMT) and on best corrected visual acuity (BCVA) changes in eyes with center-involved diabetic macular edema (CI-DME). METHODS: Fifty-seven...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PUBLISHED BY KNOWLEDGE E
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172803/ https://www.ncbi.nlm.nih.gov/pubmed/37181609 http://dx.doi.org/10.18502/jovr.v18i2.13182 |
_version_ | 1785039692780011520 |
---|---|
author | Moradian, Siamak Soheilian, Masoud Asadi, Mahsan Baghi, Abdolreza Safi, Hamid Abtahi, Seyed-Hossein |
author_facet | Moradian, Siamak Soheilian, Masoud Asadi, Mahsan Baghi, Abdolreza Safi, Hamid Abtahi, Seyed-Hossein |
author_sort | Moradian, Siamak |
collection | PubMed |
description | PURPOSE: To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well as on central macular thickness (CMT) and on best corrected visual acuity (BCVA) changes in eyes with center-involved diabetic macular edema (CI-DME). METHODS: Fifty-seven eyes of 36 patients with CI-DME were included in this prospective interventional case series. Structural optical coherence tomography (OCT) and enhanced depth imaging OCT were performed at baseline followed by three monthly 1.25 mg IVZ injections. Changes of SCT, CMT, and BCVA at each follow-up session were assessed. The association between baseline SCT and its monthly changes with final visual and anatomical outcomes were also assessed. RESULTS: CMT at baseline, and at the first, second, and third month follow-up sessions were 396 [Formula: see text] 119, 344 [Formula: see text] 115, 305 [Formula: see text] 89, and 296 [Formula: see text] 101 μm, respectively (P-value [Formula: see text] 0.001). SCT at baseline, and at months one, two, and three were 236 [Formula: see text] 47, 245 [Formula: see text] 56, 254 [Formula: see text] 54, and 241 [Formula: see text] 54 μm, respectively (P-value [Formula: see text] 0.99). Corresponding figures for BCVA were 0.58 [Formula: see text] 0.29, 0.47 [Formula: see text] 0.31, 0.4 [Formula: see text] 0.24, and 0.37 [Formula: see text] 0.23 LogMAR, respectively (P-value [Formula: see text] 0.001). There was a statistically significant positive correlation between BCVA and CMT changes following IVZ injections (P-value [Formula: see text] 0.001). However, there were no significant correlations between SCT changes and visual acuity (VA) and CMT changes following IVZ injections. CONCLUSION: IVZ improved visual outcomes and macular thickness profiles in patients with CI-DME. However, IVZ had no significant effect on SCT. Baseline SCT and its monthly changes had no association with visual and anatomical outcomes. |
format | Online Article Text |
id | pubmed-10172803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | PUBLISHED BY KNOWLEDGE E |
record_format | MEDLINE/PubMed |
spelling | pubmed-101728032023-05-12 Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes Moradian, Siamak Soheilian, Masoud Asadi, Mahsan Baghi, Abdolreza Safi, Hamid Abtahi, Seyed-Hossein J Ophthalmic Vis Res Original Article PURPOSE: To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well as on central macular thickness (CMT) and on best corrected visual acuity (BCVA) changes in eyes with center-involved diabetic macular edema (CI-DME). METHODS: Fifty-seven eyes of 36 patients with CI-DME were included in this prospective interventional case series. Structural optical coherence tomography (OCT) and enhanced depth imaging OCT were performed at baseline followed by three monthly 1.25 mg IVZ injections. Changes of SCT, CMT, and BCVA at each follow-up session were assessed. The association between baseline SCT and its monthly changes with final visual and anatomical outcomes were also assessed. RESULTS: CMT at baseline, and at the first, second, and third month follow-up sessions were 396 [Formula: see text] 119, 344 [Formula: see text] 115, 305 [Formula: see text] 89, and 296 [Formula: see text] 101 μm, respectively (P-value [Formula: see text] 0.001). SCT at baseline, and at months one, two, and three were 236 [Formula: see text] 47, 245 [Formula: see text] 56, 254 [Formula: see text] 54, and 241 [Formula: see text] 54 μm, respectively (P-value [Formula: see text] 0.99). Corresponding figures for BCVA were 0.58 [Formula: see text] 0.29, 0.47 [Formula: see text] 0.31, 0.4 [Formula: see text] 0.24, and 0.37 [Formula: see text] 0.23 LogMAR, respectively (P-value [Formula: see text] 0.001). There was a statistically significant positive correlation between BCVA and CMT changes following IVZ injections (P-value [Formula: see text] 0.001). However, there were no significant correlations between SCT changes and visual acuity (VA) and CMT changes following IVZ injections. CONCLUSION: IVZ improved visual outcomes and macular thickness profiles in patients with CI-DME. However, IVZ had no significant effect on SCT. Baseline SCT and its monthly changes had no association with visual and anatomical outcomes. PUBLISHED BY KNOWLEDGE E 2023-04-19 /pmc/articles/PMC10172803/ /pubmed/37181609 http://dx.doi.org/10.18502/jovr.v18i2.13182 Text en Copyright © 2023 Moradian et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Moradian, Siamak Soheilian, Masoud Asadi, Mahsan Baghi, Abdolreza Safi, Hamid Abtahi, Seyed-Hossein Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes |
title | Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes |
title_full | Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes |
title_fullStr | Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes |
title_full_unstemmed | Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes |
title_short | Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes |
title_sort | ziv-aflibercept in diabetic macular edema: relation of subfoveal choroidal thickness with visual and anatomical outcomes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172803/ https://www.ncbi.nlm.nih.gov/pubmed/37181609 http://dx.doi.org/10.18502/jovr.v18i2.13182 |
work_keys_str_mv | AT moradiansiamak zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes AT soheilianmasoud zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes AT asadimahsan zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes AT baghiabdolreza zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes AT safihamid zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes AT abtahiseyedhossein zivafliberceptindiabeticmacularedemarelationofsubfovealchoroidalthicknesswithvisualandanatomicaloutcomes |